Prosecution Insights
Last updated: October 02, 2026

Examiner: MIANO, JOSEPH PAUL

Tech Center 1600 • Art Units: 1631 1632

This examiner grants 36% of resolved cases

Performance Statistics

36.0%
Allow Rate
-24.0% vs TC avg
163
Total Applications
+63.3%
Interview Lift
1537
Avg Prosecution Days
Based on 111 resolved cases, 2023–2026

Rejection Statute Breakdown

4.3%
§101 Eligibility
13.0%
§102 Novelty
48.2%
§103 Obviousness
21.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18764172 CELL CULTURE METHOD AND MASKING SHEET Non-Final OA FUJIFILM CORPORATION
17112720 METHOD FOR PRODUCING HUMAN A1 ASTROCYTES, HUMAN A1 ASTROCYTES, AND METHOD FOR EVALUATING TEST SUBSTANCE Non-Final OA FUJIFILM Corporation
18643684 METHODS FOR SAMPLE PREPARATION Non-Final OA 10x Genomics, Inc.
17229746 COPPER LOSS MITIGATION Final Rejection Genentech, Inc.
17117062 IN VITRO EXPANSION OF DOPAMINERGIC SUBTYPE NEURONAL PROGENITORS DERIVED FROM PLURIPOTENT STEM CELLS Non-Final OA Wisconsin Alumni Research Foundation
18775975 GENE THERAPY DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF Non-Final OA The Regents of the University of California
17605198 MODULATING SURVIVAL OF THERAPEUTIC CELLS AND METHODS, CELLS AND NUCLEIC ACIDS RELATED THERETO Non-Final OA The Regents of the University of California
18994414 COMPOSITIONS AND METHODS FOR GROWING ESOPHAGEAL CELLS AND RELATED USES THEREOF Non-Final OA The Regents of the University of Michigan
18840007 ARTIFICIAL SERTOLI CELLS AND METHOD FOR THEIR PRODUCTION Non-Final OA The Regents of the University of Michigan
17754848 GENE TARGETS FOR MANIPULATING T CELL BEHAVIOR Non-Final OA THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
17010707 METHODS OF PREPARING T CELLS FOR T CELL THERAPY Non-Final OA Allogene Therapeutics, Inc.
17844882 PLURIPOTENT STEM CELLS INDUCING OSTEOCHONDRAL REPAIR Final Rejection TOHOKU UNIVERSITY
19300583 HEAT SHOCK INDUCIBLE CELLS AND THEIR MANUFACTURE AND USE Non-Final OA Upside Foods, Inc.
18712159 CHIMERIC HSV EXPRESSING HIL21 TO BOOST ANTI-TUMOR IMMUNE ACTIVITY Non-Final OA Research Institute at Nationwide Children's Hospital
18566001 NOVEL PLURIPOTENT CELLS Final Rejection DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY
17071020 Cell-Based Biosensor for Early Alzheimer's Disease Detection Non-Final OA University of South Carolina
19064510 SYSTEMS FOR TRANSPORT OF A BIOLOGICAL SAMPLE Final Rejection Paragonix Technologies, Inc.
19214187 MAGNETIC CAPTURE DEVICE Non-Final OA LO BIOSCIENCES, INC.
18027900 RAFT CULTURES AND METHODS OF MAKING THEREOF Final Rejection CHILDREN'S HOSPITAL MEDICAL CENTER
18260786 COMPOSITIONS FOR TREATING FRIEDREICH'S ATAXIA Final Rejection The Trustees of the University of Pennsylvania
17812146 EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEROF Final Rejection Iovance Biotherapeutics, Inc.
18462800 METHOD FOR PRODUCING BIOLOGIC PRODUCT VARIANTS Non-Final OA LONZA LTD
17578989 FUSION POLYPEPTIDE FOR IMMUNOTHERAPY Final Rejection MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
18839788 HUMAN TOOTH ORGANOIDS Non-Final OA Universiteit Hasselt
17231278 HUMAN INTESTINAL EPITHELIUM MODEL AND METHOD FOR PREPARING SAME Final Rejection KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
17905197 GENERATION OF AUTOIMMUNE INHIBITORY T CELLS BY FIBROBLAST MEDIATED EDUCATION Non-Final OA FIGENE, LLC
17996754 METHODS AND COMPOSITIONS Final Rejection Monash University
17629918 ADOPTIVE TRANSFER OF PLASMACYTOID DENDRITIC CELLS TO PREVENT OR TREAT HAIR LOSS Final Rejection Tufts Medical Center, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month